

Rutgers Cancer Institute of New Jersey  
Reporting Period: 04/01/2022 - 03/31/2023  
Reporting Prepared: 04/01/2023  
Data Table 4 – Clinical Research Protocols (CIPT)

**Interventional:**

National											Total Targeted Accrual		Cancer Center: Primary Accrual Institution		Other Accrual Institution(s)	
Specific Funding Source	Primary Site	Protocol ID	PI	Prog Code	Date Opened	Date Closed	Phase	Primary Purpose	Official Title	Multi-Inst Study?	Entire Study	Your Center	12 Months To Date	12 Months To Date	12 Months To Date	12 Months To Date
Alliance	Brain and Nervous System	NCT03224767	Agarwalla, P	CIPT	07/12/2019		II	Tre	Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas.	Yes		3	0	1		
ECOG	Other Skin	NCT03712605	Berger, A	CIPT	12/30/2019		III	Tre	A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma.	Yes		4	0	2		
NRG	Bones and Joints; Soft Tissue	NCT03217266	Berger, A	CIPT	06/18/2020	07/25/2022	I	Tre	A Phase Ib Trial of Neoadjuvant AMG 232 (KRT232) Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS).	Yes		1	0	0		
SWOG	Melanoma, Skin	NCT03860883	Berger, A	CIPT	08/12/2022		III	Tre	Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm vs 2cm Wide Excision Margins for Primary Cutaneous Melanoma.	No		10	11	11		
COG	Multiple	NCT04089358	Bhatla, T	CIPT	10/22/2022		III	Sup	COG - ALTE2031: StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors.	Yes		40	0	0		
NRG	Colon	NCT04068103	Boland, P	CIPT	01/29/2020		II/III	Tre	Phase II/III Study of Circulating tumOr DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA).	Yes		10	10	15		
CHOP	Leukemia, not otherwise specified	NCT04293562	Botwinick, M	CIPT	09/22/2020		III	Tre	A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.	Yes		1	2	12		
COG	Leukemia, other	NCT03817398	Botwinick, M	CIPT	12/20/2019		II	Tre	Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP).	Yes		5	1	1		
COG	Brain and Nervous System	NCT03871257	Botwinick, M	CIPT	01/28/2020		III	Tre	A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma.	Yes		5	0	1		
COG	Lymphoid Leukemia	NCT03914625	Botwinick, M	CIPT	08/27/2019		III	Tre	A Phase 3 Trial Investigating Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy).	Yes		20	6	14	0	3
ECOG	Multiple	171701-H	Cohen, S	CIPT	01/10/2023		II	Tre	EAY131-H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, Colorectal Adenocarcinoma, and Non Small Cell Lung Cancer).	No		1	0	0		
ECOG	Anus	NCT04166318	Deek, M	CIPT	07/21/2020		II	Tre	A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE).	Yes		3	2	2		
SWOG	Lung	NCT04155034	Deek, M	CIPT	04/30/2020		III	Tre	MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).	Yes		3	2	3		
ECOG	Lymphoid Leukemia	NCT04530565	Doraiswamy, A	CIPT	06/01/2021		III	Tre	Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults.	Yes		25	2	2		
COG	Multiple	NCT02176967	Drachtman, R	CIPT	10/03/2014		III	Tre	Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma.	Yes		3	0	1		
COG	Multiple; Leukemia, not otherwise specified	NCT02521493	Drachtman, R	CIPT	09/21/2016	04/15/2022	III	Tre	Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome.	Yes		2	0	1		

COG	Multiple	NCT02567435	Drachtman, R	CIPT	07/11/2016	03/30/2023	III	Tre	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temozolimus in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS).	Yes		5	0	1		
COG	Other Female Genital; Other Male Genital	NCT02582697	Drachtman, R	CIPT	07/29/2019		III	Tre	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.	Yes		2	1	1		
COG	Brain and Nervous System	NCT02724579	Drachtman, R	CIPT	12/01/2017		II	Tre	A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients.	Yes		1	0	0		
COG	Multiple; Leukemia, other	NCT03007147	Drachtman, R	CIPT	08/20/2018		III	Tre	International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones.	Yes		2	0	1		
COG	Multiple	NCT03126916	Drachtman, R	CIPT	08/20/2018		III	Tre	A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL).	Yes		1	1	2		
COG	Multiple	NCT03155620	Drachtman, R	CIPT	01/11/2018		N/A	Scr	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol.	Yes		5	0	3	0	2
COG	Liver	NCT03533582	Drachtman, R	CIPT	10/02/2018		II/III	Tre	Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT).	Yes		1	2	5		
COG	Multiple	NCT03959085	Drachtman, R	CIPT	01/30/2020		III	Tre	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL, Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-Ly.	Yes		10	8	18		
COG	Leukemia, other	NCT04258943	Drachtman, R	CIPT	10/07/2020		I/II	Tre	A Phase I/II Study of Bosutinib in Pediatric Patients with Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia.	Yes		1	0	0		
COG	Multiple	NCT04546399	Drachtman, R	CIPT	12/15/2020		II	Tre	A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged $\leq 1$ to $\leq 31$ Years Old with First Relapse.	Yes		2	0	3		
COG	Brain and Nervous System	NCT04576117	Drachtman, R	CIPT	03/26/2021		III	Tre	A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations.	Yes		5	0	0		
SWOG	Hodgkin's Lymphoma	NCT03907488	Drachtman, R	CIPT	09/18/2019	12/01/2022	III	Tre	A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age $\geq 12$ Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.	Yes		10	3	17		
ECOG	Multiple	NCT02465060	Ganesan, S	CIPT	10/19/2017	12/30/2022	II	Scr	Molecular Analysis for Therapy Choice (MATCH).	Yes		5	1	7		
ECOG	Multiple	NCT04628767	Ghodoussipour, S	CIPT	02/22/2023		II/III	Tre	A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy.	Yes		2	0	0		
NRG	Other Female Genital	NCT03914612	Girda, E	CIPT	09/27/2019	12/06/2022	III	Tre	A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer.	Yes		5	8	21		
NRG	Multiple	NCT03997370	Girda, E	CIPT	03/11/2020		N/A	Tre	Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin.	Yes		10	5	17		
NRG	Ovary	NCT04251052	Girda, E	CIPT	08/13/2020		N/A	Pre	A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRC1 Carriers.	Yes		6	1	4		
NRG	Other Female Genital	NCT05256225	Girda, E	CIPT	03/14/2023		II/III	Tre	A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-ZZFX (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.	Yes		4	0	0		
Alliance	Breast - Female	NCT01901094	Haffty, B	CIPT	07/17/2015	7/1/22	III	Tre	A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy.	Yes		30	0	11	0	6
Alliance	Brain and Nervous System	NCT04114981	Haffty, B	CIPT	10/13/2020	09/09/2022	III	Tre	Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease.	Yes		1	2	4		
NRG	Brain and Nervous System	NCT03180268	Haffty, B	CIPT	01/15/2019	9/14/23	III	Tre	Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma.	Yes		8	0	1		

ECOG	Lip, Oral Cavity and Pharynx	NCT03811015	Haigentz, M	CIPT	03/16/2022		III	Tre	A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC.	Yes		4	3	3			
ECOG	Lung	NCT04181060	Haigentz, M	CIPT	03/08/2021		III	Tre	Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC).	Yes		3	1	1			
NRG	Lip, Oral Cavity and Pharynx	NCT02135042	Haigentz, M	CIPT	01/23/2019		II/III	Tre	Randomized Phase II and Phase III Studies of Individualized Treatment FOR Nasopharyngeal Carcinoma Based ON Biomarker Epstein Barr Virus (EBV) DEOXYRIBONUCLEIC ACID (DNA).	Yes		2	1	6			
NRG	Other Female Genital; Cervix	NCT02466971	Hathout, L	CIPT	07/26/2019	09/22/2022	III	Tre	A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or In Combination with Intravenous Triptine in Women with Newly Diagnosed Bulky Stage IB2, or Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.	Yes		1	0	2			
NRG	Prostate	NCT04134260	Hathout, L	CIPT	06/26/2020		III	Tre	Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy.	Yes		1	2	4			
NRG	Prostate	NCT05050084	Hathout, L	CIPT	04/07/2022		III	Tre	Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE).	Yes		2	9	9			
Alliance	Colon	NCT02912559	Hochster, H	CIPT	03/12/2018	01/17/2023	III	Tre	Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair.	Yes		2	2	8			
Alliance	Colon	NCT04094688	Hochster, H	CIPT	05/11/2020	01/12/2023	III	Tre	Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS).	Yes		5	2	8			
NRG	Colon	NCT05174169	Hochster, H	CIPT	03/29/2022		II/III	Tre	Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease (CIRCULATE-US).	Yes		15	3	3			
NSABP	Colon	NCT05178576	Hochster, H	CIPT	07/11/2022	10/19/2022	II	Tre	A Single Arm Phase II Study to Evaluate Treatment with Gevokizumab in Patients with Stage II/III Colon Cancer who are ctDNA Positive after Curative Surgery and Adjuvant Chemotherapy.	Yes		6	0	0			
SWOG	Colon	NCT02997228	Hochster, H	CIPT	03/19/2018		III	Tre	A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.	Yes		2	0	0			
ECOG	Lung	NCT02201992	Jabbour, S	CIPT	12/11/2015	12/03/2020	III	Tre	A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.	Yes		5	0	3			
ECOG	Esophagus	NCT03604991	Jabbour, S	CIPT	03/13/2019		II/III	Tre	A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma.	Yes		4	1	7			
ECOG	Lung	NCT04092283	Jabbour, S	CIPT	02/18/2021		III	Tre	Randomized Phase III Trial of MEDJ4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC.	Yes		10	9	14			
NRG	Lung	NCT03811002	Jabbour, S	CIPT	01/16/2020	06/23/2022	II/III	Tre	Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab.	Yes		5	0	3			
NRG	Lip, Oral Cavity and Pharynx	NCT03952585	Kim, S	CIPT	10/22/2021		II/III	Tre	A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer.	Yes		2	0	1			
Alliance	Pancreas	NCT04340141	Langan, R	CIPT	11/23/2021		III	Tre	A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer.	Yes		3	3	5			
GOG	Corpus Uteri	NCT04393285	Leiser, A	CIPT	02/19/2021		II	Tre	A Phase II Study of Abemaciclib in Combination with Letrozole in Advanced, Recurrent or Metastatic Endometrioid Endometrial Cancer.	Yes		5	0	1			
Alliance	Breast	NCT03927027	Lue, D	CIPT	08/21/2019		III	Sup	Axillary Reverse Mapping, - A Prospective Trial To Study Rates Of Lymphedema And Regional Recurrence After Sentinel Lymph Node Biopsy And Sentinel Lymph Node Biopsy Followed By Axillary Lymph Node Dissection With And Without Axillary Reverse Mapping.	Yes		2	1	4			
Alliance	Non-Hodgkin's Lymphoma	NCT03984448	Matasar, M	CIPT	05/14/2020		II/III	Tre	Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas.	Yes		4	0	4			

ECOG	Hodgkin's Lymphoma	NCT01896999	Matasar, M	CIPT	01/06/2016		I	Tre	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma.	Yes		3	1	22			
ECOG	Non-Hodgkin's Lymphoma	NCT03267433	Matasar, M	CIPT	10/01/2018		III	Tre	A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission.	Yes		8	3	8			
SWOG	Non-Hodgkin's Lymphoma	NCT04799275	Matasar, M	CIPT	05/20/2021		II/III	Tre	A Phase II/III Randomized Study of R-miniCHOP With or Without Oral Azacitidine (CC-486) in Participants Age 75 years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements.	Yes		4	0	3			
NRG	Prostate	NCT04037254	Mattes, M	CIPT	01/11/2022		I/II	Tre	Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I).	Yes		3	0	0			
NRG	Prostate	NCT04513717	Mattes, M	CIPT	05/21/2021		III	Tre	Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*).	Yes		5	6	7			
ECOG	Prostate	NCT04423211	Mayer, T	CIPT	09/09/2021		III	Tre	Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE).	Yes		4	1	2			
COG	Kidney	NCT04322318	Moerder, S	CIPT	12/14/2021		II	Tre	Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).	Yes		2	0	0			
COG	Brain and Nervous System	NCT04684368	Moerder, S	CIPT	09/17/2021		II	Tre	A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor.	Yes		2	0	0			
COG	Brain and Nervous System	NCT05099003	Moerder, S	CIPT	07/14/2022		I/II	Tre	A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG).	Yes		5	0	0			
COG	Lung; Bones and Joints	NCT05235165	Moerder, S	CIPT	05/16/2022		III	Tre	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.	Yes		5	0	0			
COG	Soft Tissue	NCT05304585	Moerder, S	CIPT	08/29/2022		III	Tre	A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma.	Yes		3	1	1			
COG	Multiple	NCT04994132	Moerder, S	CIPT	12/09/2021		III	Tre	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS) An Intergroup NCTN Phase 3 Study.	Yes		2	2	2			
Alliance	Breast	NCT04457596	Omene, C	CIPT	08/09/2021		II/III	Tre	A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib.	Yes		4	4	9			
ECOG	Breast	NCT04001829	Omene, C	CIPT	06/04/2020	04/07/2022	II	Sup	Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women.	Yes		7	0	3			
ECOG	Breast	NCT04266249	Omene, C	CIPT	04/27/2020		II	Tre	Preoperative THP and Postoperative HP in Patients who Achieve a Pathologic Complete Response.	Yes		10	18	58			
NRG	Lip, Oral Cavity and Pharynx	NCT04333537	Roden, D	CIPT	08/19/2021		II/III	Tre	Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer.	Yes		1	0	1			
NRG	Brain and Nervous System	NCT04396860	Salacz, M	CIPT	04/07/2022	03/28/2023	II/III	Tre	A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma.	Yes		3	0	0			
NRG	Brain and Nervous System	NCT05095376	Salacz, M	CIPT	04/07/2022		III	Tre	Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma.	Yes		2	1	1			
Alliance	Kidney	NCT03793166	Saraiya, B	CIPT	02/05/2020		III	Tre	PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE].	Yes		4	3	8			

Alliance	Urinary Bladder	NCT05241860	Saraiya, B	CIPT	02/10/2023		II	Tre	A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC); A-DREAM.	Yes		2	2	2		
ECOG	Leukemia, other	NCT03504644	Schaar, D	CIPT	09/12/2019		I/II	Tre	A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia.	Yes		2	2	4		
NSABP	Breast	NCT03412643	Schleicher, L	CIPT	07/30/2021		II	Tre	An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1).	Yes		1	0	1		
COG	Lymphoid Leukemia	NCT02981628	Sharma, A	CIPT	10/05/2017		II	Tre	A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).	Yes		1	0	2		
COG	Multiple	NCT03067181	Sharma, A	CIPT	07/13/2017		III	Tre	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.	Yes		1	3	5		
COG	Multiple; Lymphoid Leukemia	NCT04759586	Sharma, A	CIPT	08/10/2021		III	Tre	A Randomized Phase 3 Trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma.	Yes		2	0	0		
NRG	Breast - Male; Breast - Female	NCT02488967	Toppmeyer, D	CIPT	03/19/2018		III	Tre	A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer.	Yes		2	0	5		
<b>Externally Peer-Reviewed</b>											<b>Total Targeted Accrual</b>		<b>Cancer Center: Primary Accrual Institution</b>		<b>Other Accrual Institution(s)</b>	
<b>Specific Funding Source</b>	<b>Primary Site</b>	<b>Protocol ID</b>	<b>PI</b>	<b>Prog Code</b>	<b>Date Opened</b>	<b>Date Closed</b>	<b>Phase</b>	<b>Primary Purpose</b>	<b>Official Title</b>	<b>Multi-Inst Study?</b>	<b>Entire Study</b>	<b>Your Center</b>	<b>12 Months To Date</b>	<b>12 Months To Date</b>	<b>12 Months To Date</b>	<b>12 Months To Date</b>
Melanoma and Skin Cancer	Melanoma, Skin	NCT03860883	Berger, A	CIPT	07/08/2020	08/12/2022	III	Tre	A Phase III, Multi-Centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma.	Yes		10	2	43		
ACCRU	Colon	NCT03992456	Boland, P	CIPT	02/25/2021	07/15/2022	II	Tre	A Randomized, Phase II Open Label Study of Panitumumab Rechallenge Versus Standard Therapy after Progression on Anti-EGFR Therapy in Patients with Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer.	Yes		7	0	1		
BTCRC	Pancreas	NCT03861702	Boland, P	CIPT	12/01/2020	03/03/2023	II	Tre	A Phase II Study to Evaluate the Efficacy of Liposomal Irinotecan in Combination with Oxaliplatin, Leucovorin, and 5-Fluorouracil for Patients with Locally Advanced Pancreatic Carcinoma.	Yes		4	0	1		
Criterion	Colon	NCT05167409	Boland, P	CIPT	07/13/2022		II	Tre	A Phase II Study (with Safety Run-In) of ALX148 in Combination with Cetuximab and Pembrolizumab in Patients with Refractory Microsatellite Stable Metastatic Colorectal Cancer.	Yes		8	2	2		
Roswell Park Cancer Inst	Colon	NCT04109924	Boland, P	CIPT	05/11/2020		II	Tre	A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pretreated Metastatic Colorectal Cancer.	Yes		8	0	20		
NMDP	Multiple	NCT01351545	Braunschweig, I	CIPT	09/30/2011		IV	Tre	A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications.	Yes		500	0	24		
Dana-Farber	Multiple	NCT03020030	Cole, P	CIPT	02/22/2019	09/13/2022	III	Tre	Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents.	Yes		15	6	32		
SickKids Research Inst.	Leukemia, other; Leukemia, not otherwise specified	NCT04929899	Devine, K	CIPT; CPC	09/20/2021		N/A	Hsr	Improving Chemotherapy-Induced Nausea Control Through Bright Ideas®-CIN Training: A Feasibility Study in Children Receiving Oral Chemotherapy.	Yes		10	5	5		
BTCRC	Non-Hodgkin's Lymphoma	NCT04431635	Evens, A	CIPT	08/19/2021		I	Tre	Phase IB Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination with the Immunotherapeutic Agents Nivolumab and Rituximab in Patients with Relapsed/Refractory Indolent Lymphoma.	Yes		4	0	0		
University of Wisconsin, Madison	Multiple	NCT05551936	Evens, A	CIPT	03/03/2023		I/II	Tre	A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma.	Yes		12	0	0		

PCORI; RTOG	Breast - Male; Breast - Female	NCT02603341	Haffty, B	CIPT	05/13/2016		III	Tre	Pragmatic Phase III Randomized Trial of Proton vs Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation.	Yes		3	0	19		
BTCRC	Lung	NCT04317534	Haigentz, M	CIPT	11/30/2020		II	Tre	A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm.	Yes		18	4	4		
BTCRC	Lung	NCT04367311	Haigentz, M	CIPT	12/04/2020		II/III	Tre	A Phase II Study of Adjuvant Treatment with Cisplatin-Based Chemotherapy plus Concomitant Atezolizumab in Patients with Stage I (tumors equal to or greater than 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-Small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA).	Yes		3	3	4		
PrECOG	Lung	NCT04334759	Haigentz, M	CIPT	04/27/2022		III	Tre	Durvalumab (MEDI4736) With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma.	Yes		2	2	2		
BTCRC	Liver	NCT04829383	Hochster, H	CIPT	03/23/2021		II	Tre	A Phase II Study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial).	Yes	50	2	1	1		
Criterion	Colon	NCT04169347	Hochster, H	CIPT	12/02/2019		II	Tre	Phase II Pilot Study of FOLFOXIRI plus Panitumumab in Metastatic RAS Wild Type, Left-Sided Colorectal Cancer.	Yes	35	3	1	6		
BTCRC	Lung	NCT03575793	Jabbour, S	CIPT	07/23/2018		I/II	Tre	A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer.	Yes	55	4	1	6		
CTEP	Stomach; Esophagus	NCT03008278	Jabbour, S	CIPT	04/27/2018	05/25/2022	I/II	Tre	A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma.	Yes		2	0	1		
CTEP	Multiple	NCT04068194	Jabbour, S	CIPT	02/21/2020		I/II	Tre	A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.	Yes	92	4	2	12		
CTEP	Breast	NCT04090398	Jabbour, S	CIPT	03/13/2020		II	Tre	Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer.	Yes	70	6	0	2		
Moffitt	Breast - Male; Breast - Female	NCT03384914	Kowzun, M	CIPT	08/29/2019	08/02/2022	II	Tre	A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer.	Yes		5	2	6		
Mattie Miracle Cancer Foundation	Multiple	002167	Long-Traynor, K	CIPT	09/21/2021		N/A	Sup	Feasibility of a Peer-to-Peer Parent Mentoring Program for Parents of Children Recently Diagnosed with Cancer.	No	40	10	11	25		
CTEP	Lip, Oral Cavity and Pharynx; Larynx	NCT05172245	Mattes, M	CIPT	05/31/2022		I	Tre	Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.	Yes	46	10	1	1		
BTCRC	Breast - Male; Breast - Female	NCT03393845	Omene, C	CIPT	11/21/2017		II	Tre	A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients.	Yes	47	10	2	13		
Hoosier Cancer Research Network	Breast	NCT05467891	Omene, C	CIPT	02/17/2023		II	Tre	A Phase II Study of Ribociclib And Endocrine Treatment of Physician s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer	Yes		1	0	0		
Quantum Leap Healthcare Collaborative	Breast	NCT01042379	Omene, C	CIPT	09/20/2021		I/II	Tre	I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And molecular Analysis 2).	Yes		6	28	42		
PCORI	Prostate	NCT03561220	Parikh, R	CIPT	11/05/2019	10/31/2022	III	Tre	A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer(COMPPARE).	Yes		5	2	27		
CTEP	Prostate	NCT03317392	Saraiya, B	CIPT	10/21/2019		I/II	Tre	NCI/CTEP #10096: A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE).	Yes		1	4	9		
Columbia University	Kidney	NCT04322955	Saraiya, B	CIPT	02/08/2021		II	Tre	Cyto-KIK TRIAL: (CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib).	Yes		2	3	9		
New Jersey Health Foundation Inc.	Multiple	132006	Saraiya, B	CIPT; CPC	01/12/2021		N/A	Hsr	Values and Options in Cancer Care 2.	No	56	56	18	21		
CTEP	Leukemia, other	NCT03772925	Schaar, D	CIPT	12/13/2019	10/19/2022	I	Tre	A Phase 1 Study of MLN4924 (pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.	Yes		2	2	10		

CTEP	Kidney	NCT01130519	Stephenson, R	CIPT	05/31/2022		II	Tre	A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer.	Yes		2	1	1		
Northwestern University	Prostate	NCT03012321	Stephenson, R	CIPT	07/28/2017		II	Tre	A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects.	Yes		6	0	2		
Dana Farber	Multiple	NCT05225428	Toppmeyer, D	CIPT	11/15/2022		N/A	Hsr	Video Education with Result Dependent disclosure (VERDI)	Yes	662	10	10	10		
Sarah Cannon Development Innovations, LLC	Breast	NCT04699630	Toppmeyer, D	CIPT	05/17/2021		II	Tre	A Phase II Study of U3-1402 in Patients with Metastatic Breast Cancer.	Yes		2	0	4		
<b>Institutional</b>											<b>Total Targeted Accrual</b>		<b>Cancer Center: Primary Accrual Institution</b>		<b>Other Accrual Institution(s)</b>	
<b>Specific Funding Source</b>	<b>Primary Site</b>	<b>Protocol ID</b>	<b>PI</b>	<b>Prog Code</b>	<b>Date Opened</b>	<b>Date Closed</b>	<b>Phase</b>	<b>Primary Purpose</b>	<b>Official Title</b>	<b>Multi-Inst Study?</b>	<b>Entire Study</b>	<b>Your Center</b>	<b>12 Months To Date</b>	<b>12 Months To Date</b>	<b>12 Months To Date</b>	<b>12 Months To Date</b>
Nateria, Inc.	Multiple	NCT04929015	Alexander, H	CIPT	04/29/2021		II	Tre	PERitoneal Carcinomatosis LEveraging ctDNA guided treatment Study in GI Cancer (PERICLES Study).	No	30	30	7	18		
CINJ	Pancreas	NCT04672005	Berim, L	CIPT	12/14/2020		II	Tre	Modified FOLFIRINOX Alternated with Biweekly Gemcitabine plus Nab-Paclitaxel in Untreated Metastatic Adenocarcinoma of the Pancreas.	No	30	20	10	19		
CINJ	Stomach; Esophagus	NCT05332002	Boland, P	CIPT	04/29/2022		II	Tre	A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE).	No	38	22	3	3		
CINJ	Multiple	NCT05419518	Deek, M	CIPT	12/16/2022		II	Tre	Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metastases: A Phase II Study.	No	124	30	2	2		
CINJ	Multiple	NCT02688517	Ganesan, S	CIPT; GICG	02/22/2013		N/A	Dia	Targeted Genomic Analysis of Human Cancers.	Yes	2000	2000	110	1136	0	52
CINJ	Breast	NCT05333874	George, M	CIPT	04/07/2022	11/28/2022	II	Tre	Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage Breast Cancer.	No	37	10	35	35		
CINJ	Breast	NCT05559164	George, M	CIPT	09/08/2022		II	Tre	Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy.	No	57	15	10	10		
ONCOLYTICS BIOTECH	Breast	NCT04445844	George, M	CIPT	07/13/2020		II	Tre	Phase 2 Study of INCMGA00012 and the Oncolytic Virus Pelareorep in Metastatic Triple Negative Breast Cancer.	Yes	25	10	1	6	2	4
CINJ	Prostate	NCT03456843	Ghodoussipour, S	CIPT	03/14/2018		II	Tre	SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined with Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men with Newly Diagnosed Metastatic Prostate Cancer.	Yes	190	4	3	50	0	40
Janssen Research & Development, LLC	Prostate	NCT02949284	Ghodoussipour, S	CIPT	06/20/2017		II	Tre	Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination with Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men with High-Risk Prostate Cancer.	Yes	90	20	9	63	4	4
CINJ	Multiple	NCT03428802	Girda, E	CIPT	03/08/2018		II	Tre	A Basket Trial of Pembrolizumab in Patients with Advanced Solid Tumors and Genomic Instability.	Yes	40	2	0	15	3	3
CINJ	Pancreas	NCT05415917	Gulhati, P	CIPT	06/28/2022		II	Tre	Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy.	No	75	50	0	0		
CINJ	Breast	NCT04871516	Haffty, B	CIPT	05/18/2021		II	Tre	A Phase II Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Breast Cancer Patients.	No	98	98	40	67		
CINJ	Lip, Oral Cavity and Pharynx	NCT05335148	Haffty, B	CIPT	05/10/2022		II	Tre	A Phase I Study to Evaluate the Safety of Colechicine for Treatment and Prevention of Radiation-Induced Dermatitis.	No	30	10	8	8		
CINJ	Lung	NCT05358548	Haigentz, M	CIPT	04/28/2022		II	Tre	Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATeH).	No	150	40	23	23		
CINJ	Prostate	NCT04253483	Hathout, L	CIPT	07/17/2019		II	Tre	A Phase II Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer.	No	15	2	4	13		
CINJ	Multiple	NCT05483491	Hinrichs, C	CIPT; CMI	10/06/2022		I	Tre	A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.	No	30	5	0	0		
CINJ	Multiple	NCT05686226	Hinrichs, C	CIPT; CMI	03/02/2023		II	Tre	A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers	No	20	0	0	0		

CINJ	Colon	072303	Hochster, H	CIPT	03/31/2023		II	Tre	Sequential Combined TAS-102 and Oxaliplatin Alternating with TAS-102 and Irinotecan (Sequential TASOXIRI) with Bevacizumab for Late-Line Metastatic Colorectal Cancer.	Yes	50	0	0	0		
CINJ	Colon	NCT04294264	Hochster, H	CIPT	02/12/2019	03/31/2023	II	Tre	TAS-102 In Combination With Oxaliplatin (TAS-OX) For Refractory Metastatic Colorectal Cancer.	Yes	70	33	16	54		
CINJ	Pancreas	NCT05296421	Hochster, H	CIPT; CMI	03/14/2022		N/A	Bas	Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations.	No	16	16	1	1		
CINJ	Colon	NCT05296681	Hochster, H	CIPT	05/03/2022		II	Tre	A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery.	No	42	20	5	5		
CINJ	Lip, Oral Cavity and Pharynx	NCT04920344	Imanguli, M	CIPT	07/19/2021		II	Tre	Swallowing Outcomes and Circulating Tumor DNA in Patients with HPV Related Oropharyngeal Cancer Treated with Transoral Surgery and Reduced Intensity Adjuvant Therapy.	No	33	33	9	14		
CINJ	Stomach	NCT03257163	Jabbour, S	CIPT	09/29/2017		II	Tre	A Phase II Study of Preoperative Pembrolizumab for Mismatch Repair Deficient, Epstein-Barr Virus Positive and/or PD-L1 Positive Gastric Cancer followed by Chemotherapy and Chemoradiation with Pembrolizumab.	Yes	40	2	4	16	5	21
CINJ	Lung	NCT04751747	Jabbour, S	CIPT	02/11/2021		II	Tre	The Role of Adaptive Radiation Planning in Patients with Non-Small Cell Lung Cancer on Radiation Induced Toxicity .	No	34	34	16	27		
CINJ	Rectum	NCT05358704	Jabbour, S	CIPT	05/13/2022		II	Tre	Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.	No	38	28	9	9		
Natera	Liver	NCT05366829	Jabbour, S	CIPT	07/25/2022		II	Tre	A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.	Yes	45	20	2	2	0	0
CINJ	Multiple	NCT05351294	Mattes, M	CIPT	07/13/2022		III	Tre	Impact of Early Radiation Oncology Involvement as Part of a Multidisciplinary Palliative Care Team on Quality of Life Among Diverse Patients with Advanced/Metastatic Malignancies.	No	156	156	26	26		
NJCCR	Multiple	NCT05352451	Saraiya, B	CIPT; CPC	05/09/2022		II	Sup	Values and Options in Cancer Care 2 (VOICE 2) - A Randomized Pilot Study.	No	40	40	5	5		
CINJ	Multiple	NCT04211259	Shah, M	CIPT	04/18/2022		II	Tre	The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization.	No	70	70	7	7		
CINJ	Multiple	112005	Sharma, A	CIPT	06/19/2021		N/A	Hsr	Use of Meditation Mobile Application in Pediatric Cancer Survivors.	Yes	25	15	9	25		
CINJ	Multiple	NCT03272633	Strair, R	CIPT	10/26/2020	06/30/2022	I	Tre	Post-Transplant Use of Irradiated Haplo-Allogeneic Cells.	No	20	20	0	4		
CINJ	Leukemia, other	NCT04146038	Strair, R	CIPT	10/26/2020	06/30/2022	II	Tre	Salsalate + Venetoclax/Decitabine for Patients with Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease.	No	20	20	0	5		
<b>Industry</b>											<b>Total Targeted Accrual</b>		<b>Cancer Center: Primary Accrual Institution</b>		<b>Other Accrual Institution(s)</b>	
<b>Specific Funding Source</b>	<b>Primary Site</b>	<b>Protocol ID</b>	<b>PI</b>	<b>Prog Code</b>	<b>Date Opened</b>	<b>Date Closed</b>	<b>Phase</b>	<b>Primary Purpose</b>	<b>Official Title</b>	<b>Multi-Inst Study?</b>	<b>Entire Study</b>	<b>Your Center</b>	<b>12 Months</b>	<b>To Date</b>	<b>12 Months</b>	<b>To Date</b>
Davol Inc.	Multiple	NCT03911700	Alexander, H	CIPT	02/02/2023		III	Pre	Prophylactic Reinforcement of Ventral Abdominal Incisions Trial (PREVENT): Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy.	No		5	0	0		
Philogen	Melanoma, Skin	NCT03567889	Berger, A	CIPT	07/22/2020	03/27/2023	III	Tre	An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage IIIB/C Melanoma Patients.	Yes		4	0	4		
Gritstone bio, Inc.	Colon; Rectum	NCT05141721	Berim, L	CIPT	03/17/2022		II/III	Tre	A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer.	Yes		10	6	6		
MacroGenics	Stomach; Esophagus	NCT04082364	Boland, P	CIPT	01/08/2020		II/III	Tre	A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-Naive, HER2-Positive Gastric or Gastroesophageal Junction Cancer.	Yes		4	0	1		
Merck & Co., Inc.	Colon	NCT05064059	Boland, P	CIPT	12/07/2021	07/29/2022	III	Tre	A Phase 3 Study of MK-4280A (coformulated favezelimab [MK-4280] plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD L1 Positive Colorectal Cancer.	Yes		5	4	6		



Processa Pharmaceuticals, Inc.	Multiple	NCT04861987	Boland, P	CIPT	09/10/2021		I	Tre	A Phase 1b Dose-Escalation Study of the Safety and Pharmacokinetics of Fixed-Dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors.	Yes		15	2	3		
Janssen Research & Development, LLC	Multiple Myeloma	NCT04133636	Braunschweig, I	CIPT	02/13/2020	03/17/2023	II	Tre	A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma.	Yes		2	1	4		
Novartis Pharmaceuticals	Non-Hodgkin's Lymphoma; Lymphoid Leukemia	NCT03601442	Braunschweig, I	CIPT	09/10/2019		N/A	Tre	Managed Access Program (MAP) to Provide Access to CTL019, for Acute Lymphoblastic Leukemia (ALL) or Large B-cell Lymphoma Patients without of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release.	Yes		2	0	8		
xCures	Multiple	NCT04566393	Cohen, S	CIPT	12/22/2020		N/A	Tre	Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies.	Yes		1	3	6		
Gilead Sciences, Inc	Myeloid and Monocytic Leukemia; Leukemia, other	NCT05079230	Doraiswamy, A	CIPT	07/18/2022		III	Tre	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy.	Yes		12	3	3		
Hutchison MediPharma Limited	Leukemia, other	NCT04762602	Doraiswamy, A	CIPT	02/17/2021		I	Tre	A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations.	Yes		5	1	2		
COG	Leukemia, other	NCT02723994	Drachtman, R	CIPT	12/14/2016	11/28/2022	II	Tre	A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High Risk CRLF-2 Rearranged and or JAK Pathway-Mutant Acute Lymphoblastic Leukemia.	Yes		2	0	5		
Merck & Co., Inc.	Hodgkin's Lymphoma	NCT03407144	Drachtman, R	CIPT	10/22/2019		II	Tre	An Open-Label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy.	Yes		5	0	1		
K-Group Beta, Inc.	Ovary	NCT05198804	Einstein, M	CIPT	11/08/2022		I/II	Tre	A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer.	Yes		5	0	0		
Papivax Biotech Inc.	Cervix	NCT03911076	Einstein, M	CIPT	04/05/2022	06/09/2022	II	Tre	A Randomized Double-Blind, Placebo-Controlled Phase II Trial with Safety Run-In of intramuscular pNGVL4a-Sig/E7(detox)/HSP70 and TA-CIN for the Treatment of Patients with HPV16+ Atypical Squamous Cells of Undetermined Significance (ASCUS) or Cannot Exclude High Grade SIL (ASC-H) Cytology or Low-Grade Squamous Intraepithelial Lesion (LSIL).	Yes		0	0	0		
Seattle Genetics	Hodgkin's Lymphoma	NCT01716806	Evens, A	CIPT	07/23/2020	08/01/2022	II	Tre	A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Older Patients or Patients with Significant Comorbidities Ineligible for Standard Chemotherapy.	Yes		4	0	0		
Bristol Myers Squibb	Breast	NCT04109066	George, M	CIPT	02/26/2020	04/07/2022	III	Tre	A Randomized, Multicenter, Double-Blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer.	Yes		10	0	5		
Hoffman La Roche	Breast	NCT04961996	George, M	CIPT	04/08/2022		III	Tre	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.	Yes		24	15	15		
OBI Pharma	Breast	NCT03562637	George, M	CIPT	11/24/2020		III	Tre	A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer.	Yes		6	2	2		
PrECOG	Breast	NCT04215146	George, M	CIPT	10/22/2020	05/25/2022	II	Tre	A Study to Assess Overall Response Rate By Inducing An Inflammatory Phenotype in Metastatic Breast Cancer with the Oncolytic Reovirus Pelareorep in Combination with anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study.	Yes		8	0	2		
Seattle Genetics	Breast	NCT05132582	George, M	CIPT	03/04/2022		III	Tre	A Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05).	Yes		6	2	3		

Triumvira Immunologies, Inc.	Multiple	NCT04727151	George, M	CIPT	05/05/2022		I/II	Tre	A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2).	Yes		4	2	2		
Bristol Myers Squibb	Urinary Bladder	NCT04209114	Ghodoussipour, S	CIPT	02/13/2020		III	Tre	A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214 Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible.	Yes		5	0	2		
Merck & Co., Inc.	Urinary Bladder	NCT03711032	Ghodoussipour, S	CIPT	12/24/2018		III	Tre	A Phase 3, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-Muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676).	Yes		5	2	5		
Adlai Nortye USA Inc	Multiple	NCT04975958	Girda, E	CIPT	10/20/2021		I	Tre	A Open-Label, Multicenter, Phase I Study of AN2025 and AN0025 in Double Combination with Atezolizumab and in Triple Combination with Atezolizumab in Patients with Advanced Solid Tumors.	Yes		4	6	14		
Astellas Pharma Global De	Multiple	NCT03799003	Girda, E	CIPT	04/15/2021	04/05/2022	I	Tre	A Phase 1b Study of ASP1951, a G1TR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors.	Yes		6	0	2		
Boston Biomedical, Inc.	Other Female Genital; Ovary	NCT03311334	Girda, E	CIPT	10/20/2020	03/06/2023	I/II	Tre	A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors.	Yes		4	0	1		
Genentech, Inc.	Multiple	NCT04589845	Girda, E	CIPT	12/11/2020		II	Tre	Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial.	Yes		4	0	2		
I-Mab Biopharma Co. Ltd.	Multiple	NCT04900818	Girda, E	CIPT	11/12/2021		I	Tre	A Phase I Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors.	Yes		4	5	6		
Incyte Corporation	Multiple	NCT03762447	Girda, E	CIPT	11/20/2019		I	Tre	A Phase I Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants with Advanced Solid Tumors.	Yes		4	0	10		
Inspira, Inc.	Multiple	NCT02922764	Girda, E	CIPT	09/15/2022		I	Tre	A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies.	Yes		3	0	0		
Merck & Co., Inc.	Multiple	NCT03486873	Girda, E	CIPT	11/02/2018		III	Tre	A Multicenter, Open Label, Phase III Extension Trial to Study the Long-Term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.	Yes		10	0	9		
Merck & Co., Inc.	Ovary	NCT05446870	Girda, E	CIPT	08/29/2022		II	Tre	A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer.	Yes		4	1	1		
Northwell Health	Other Female Genital	NCT04080284	Girda, E	CIPT	02/18/2022		II/III	Tre	Trial of Maintenance with Niraparib in patients with stage III, stage IV or platinum-sensitive Recurrent Uterine Serous Carcinoma.	Yes		2	2	3		
Nurix Therapeutics Inc.	Multiple	NCT05107739	Girda, E	CIPT	12/22/2021		I	Tre	A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults with Advanced Malignancies.	Yes		2	0	1		
Regeneron Pharmaceuticals	Multiple	NCT04626635	Girda, E	CIPT	02/19/2021		I/II	Tre	A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors.	Yes		4	5	9		
Amgen	Multiple	NCT05094336	Goel, S	CIPT	02/02/2023		I	Tre	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and In Combination with Docetaxel in Subjects with Advanced MTAP-Null Solid Tumors.	Yes		2	0	0		
Eisai Inc.	Multiple	NCT05091346	Goel, S	CIPT	10/25/2022		I/II	Tre	An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors.	Yes		5	0	0		
Exelixis	Multiple	NCT03845166	Goel, S	CIPT	01/06/2023		I	Tre	A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors.	Yes		2	0	0		
InnoCare Pharma Inc.	Multiple	NCT04565275	Goel, S	CIPT	11/15/2022		I/II	Tre	A Multi-Center Open-Label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients with Advanced Solid Tumors and FGF/FGFR Gene Alterations.	Yes		2	2	2		

Mabspace Biosciences (Suzhou) Co., Limited	Multiple	NCT04396821	Goel, S	CIPT	03/31/2023		I	Tre	A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 in Patients with Locally Advanced or Metastatic Solid Tumors.	Yes		2	0	0			
Pionyr Immunotherapeutics	Multiple	NCT04682431	Goel, S	CIPT	02/08/2023		I	Tre	A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors.	Yes		3	1	1			
QSAM THERAPEUTICS, INC.	Multiple	052201	Goel, S	CIPT	01/27/2023		I	Tre	A Dose Finding Study of CycloSam® (153Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewings Sarcoma, and other solid tumor(s) to the bone all eligible).	Yes		3	0	0			
Takeda Development Center Americas, Inc.	Multiple	NCT04381650	Goel, S	CIPT	11/30/2022		I	Tre	A Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors.	Yes		3	0	0			
TransThera Biosciences	Multiple	NCT04742959	Goel, S	CIPT	06/23/2021		I/II	Tre	A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients with Advanced Solid Tumors.	Yes		7	28	37			
Xilio Development, Inc.	Multiple	NCT05052268	Goel, S	CIPT	03/09/2023		I/II	Tre	A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors.	Yes		2	0	0			
Amgen	Lung	NCT04933695	Haigentz, M	CIPT	01/27/2022	11/18/2022	II/III	Tre	A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12CMutation in Need of First-line Treatment (CodeBreak 201).	Yes		2	0	0			
Amgen	Lung	NCT05361395	Haigentz, M	CIPT	02/16/2023		I/II	Tre	A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer.	Yes		3	1	1			
AstraZeneca	Lung	NCT05048797	Haigentz, M	CIPT	09/27/2022		III	Tre	An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04).	Yes		1	0	0			
AstraZeneca	Lung	NCT05261399	Haigentz, M	CIPT	07/25/2022		III	Tre	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).	Yes		1	1	1			
BeiGene, Ltd.	Lung	NCT04047862	Haigentz, M	CIPT	03/23/2021		I	Tre	Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors.	Yes		3	0	3			
Janssen Research & Development, LLC	Lung	NCT05498428	Haigentz, M	CIPT	02/24/2023		II	Tre	A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.	Yes		3	0	0			
Merck & Co., Inc.	Lip, Oral Cavity and Pharynx; Larynx	NCT04428151	Haigentz, M	CIPT	10/25/2021		II	Tre	A Phase 2, Randomized, Open-Label Three-Arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) that Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 inhibitors).	Yes		6	0	0			
AstraZeneca	Liver	NCT03847428	Hochster, H	CIPT	05/11/2020	04/13/2022	III	Tre	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)	Yes		4	0	3			
Compass Therapeutics	Other Digestive Organ	NCT05506943	Hochster, H	CIPT	02/21/2023		II/III	Tre	A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen.	Yes		4	0	0			

Mirati Therapeutics, Inc.	Colon	NCT04793958	Hochster, H	CIPT	05/17/2021		III	Tre	A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy.	Yes		3	0	1		
OBI Pharma	Multiple	NCT03592264	Hochster, H	CIPT	01/28/2022		I/II	Tre	A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors.	Yes		5	0	0		
Daiichi Pharmaceuticals	Colon	NCT04479436	Hochster, H	CIPT	10/22/2020	04/12/2022	II	Tre	A Multi-Center, Open-Label, Phase 2 Study to Evaluate Safety and Efficacy of U3-1402 in Subjects with Advanced or Metastatic Colorectal Cancer (CRC).	Yes		3	0	2		
Isofol Medical AB	Colon	NCT03750786	Hochster, H	CIPT	01/25/2019	05/27/2021	III	Tre	A Randomized, Multicenter, Parallel-Group, Phase III Study to Compare the Efficacy of Arfolitixorin versus Leucovorin in Combination with 5-Fluorouracil, Oxaliplatin, and Bevacizumab in Patients with Advanced Colorectal Cancer.	Yes		10	0	10		
Merck & Co., Inc.	Lung	NCT03924869	Jabbour, S	CIPT	09/30/2019		III	Tre	A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non-Small Cell Lung Cancer (NSCLC).	Yes		2	0	2		
Merck & Co., Inc.	Esophagus	NCT04210115	Jabbour, S	CIPT	02/10/2022		III	Tre	A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy.	Yes		2	0	0		
Merck & Co., Inc.	Lung	NCT04380636	Jabbour, S	CIPT	08/26/2020		III	Tre	A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC).	Yes		3	4	9		
Merck & Co., Inc.	Lung	NCT04624204	Jabbour, S	CIPT	10/22/2021		III	Tre	A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC).	Yes		4	0	0		
Merck & Co., Inc.	Lung	NCT05298423	Jabbour, S	CIPT	08/08/2022		III	Tre	Open-Label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC.	Yes		4	0	0		
Alkermes, Inc.	Ovary	NCT05092360	Leiser, A	CIPT	09/20/2022		III	Tre	A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7).	Yes		3	2	2		
Aravive, Inc.	Ovary	NCT04729608	Leiser, A	CIPT	01/21/2022	12/07/2022	III	Tre	A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer.	Yes		8	4	5		
OncoQuest Pharmaceuticals Inc	Other Female Genital; Ovary	NCT04498117	Leiser, A	CIPT	04/26/2022		I/II	Tre	A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5).	Yes		8	1	1		
ACCRU	Liver	NCT05199285	Li, S	CIPT	01/19/2023		I/II	Tre	A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.	Yes	40	3	1	1		
Amgen	Multiple	NCT02303821	Masterson, M	CIPT	11/19/2021		I/II	Tre	Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia.	Yes		2	0	0		
Hoffman La Roche	Non-Hodgkin's Lymphoma	NCT04077723	Matasar, M	CIPT	03/01/2022		I	Tre	A Phase Ib, Open-Label, Dose-Escalation, Multicenter Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous Glofitamab Following Obinutuzumab Pretreatment In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma.	Yes		4	0	1		
I-Mab Biopharma Co. Ltd.	Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma	NCT03934814	Matasar, M	CIPT	06/01/2021	09/13/2022	I	Tre	A Phase I Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma.	Yes		3	0	6		

Merck & Co., Inc.	Multiple	NCT05005442	Matasar, M	CIPT	03/18/2022		II	Tre	A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies.	Yes		4	2	2		
Regeneron Pharmaceuticals	Non-Hodgkin's Lymphoma; Lymphoid Leukemia	NCT02290951	Matasar, M	CIPT	01/08/2015		I	Tre	An Open-Label, Multi-center Phase I Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 bispecific Monoclonal Antibody, in Patients with CD20+ B-cell Malignancies Previously Treated with CD20 Directed Antibody Therapy.	Yes		8	1	48		
Curium US LLC	Prostate	NCT05204927	Mayer, T	CIPT	04/28/2022		III	Tre	A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer (ECLIPSE).	Yes		8	9	9		
Merck & Co., Inc.	Prostate	NCT02861573	Mayer, T	CIPT	06/08/2017		I/II	Tre	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC).	Yes		6	0	6		
Pfizer	Multiple	NCT03709680	Moerdler, S	CIPT	08/28/2019		I	Tre	Phase 1 Study To Evaluate the Safety and Pharmacokinetics of Palbociclib (IBRANCE®) in Combination with Irinotecan (IRN) and Temozolomide (TMZ) in Pediatric Patients with Recurrent or Refractory Solid Tumors.	Yes		1	0	1		
Turning Point Therapeutics, Inc.	Multiple	NCT03093116	Moerdler, S	CIPT	11/22/2019		I/II	Tre	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1).	Yes		3	0	0		
Turning Point Therapeutics, Inc.	Multiple	NCT04094610	Moerdler, S	CIPT	01/28/2020		I/II	Tre	A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations.	Yes		2	0	0		
ALX OnCology	Lung	NCT04675294	Nehra, A	CIPT	02/08/2023		II	Tre	A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma.	Yes		3	1	1		
Merck & Co., Inc.	Lip, Oral Cavity and Pharynx	NCT03765918	Nehra, A	CIPT	02/01/2022		III	Tre	A Phase III, Randomized, Open-Label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC).	Yes		2	3	5		
Gilead Sciences, Inc	Breast	NCT05382286	Omene, C	CIPT	09/21/2022		III	Tre	GS-US-592-6173 (ASCENT-04) A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	Yes		3	1	1		
Gilead Sciences, Inc	Breast	NCT05382299	Omene, C	CIPT	07/05/2022		III	Tre	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1.	Yes		3	0	0		
Hoffman La Roche	Non-Hodgkin's Lymphoma	NCT04408638	Palmisiano, N	CIPT	06/01/2021	11/10/2022	III	Tre	A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	Yes		3	0	2		
CNS Pharmaceuticals	Brain and Nervous System	NCT04762069	Salacz, M	CIPT	12/03/2021		III	Tre	A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy.	Yes		3	1	1		
Merck & Co., Inc.	Kidney	NCT04586231	Saraiya, B	CIPT	03/03/2021		II/III	Tre	An Open-Label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy.	Yes		2	2	3		

Merk & Co., Inc.	Kidney	NCT05239728	Saraiya, B	CIPT	04/04/2022		III	Tre	A Multicenter, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy.	Yes		12	7	7		
Regeneron Pharmaceuticals	Prostate	NCT05125016	Saraiya, B	CIPT	02/23/2022		I/II	Tre	Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer.	Yes		3	2	2		
AbbVie, Inc.	Leukemia, not otherwise specified	NCT04102020	Schaar, D	CIPT	03/03/2022		III	Tre	Randomized, Double-Blind, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy.	Yes		3	0	0		
Incyte Corporation	Leukemia, other	NCT04279847	Schaar, D	CIPT	10/15/2021	12/02/2022	I	Tre	A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis.	Yes		2	0	0		
Novartis Pharmaceuticals	Leukemia, other	NCT04666259	Schaar, D	CIPT	09/16/2021	10/14/2022	III	Tre	An Open Label, Multi-Center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T3151 Mutation (AIM4CML).	Yes		2	0	1		
Rigel Pharmaceuticals, Inc	Other Hematopoietic	NCT05308264	Schaar, D	CIPT	11/01/2022		I	Tre	An Open-Label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes (LR MDS) Who are Refractory/Resistant to Prior Therapies.	Yes		1	0	0		
SELLAS Life Sciences Group, Inc.	Leukemia, other	NCT04229979	Schaar, D	CIPT	06/10/2021	06/08/2022	III	Tre	A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy.	Yes		2	0	0		
Syndax Pharmaceuticals	Leukemia, other; Leukemia, not otherwise specified	NCT04710576	Schaar, D	CIPT	11/18/2021	08/09/2022	II	Tre	A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at Least 2 Lines of Systemic Therapy.	Yes		10	2	2		
AbbVie, Inc.	Multiple Myeloma	NCT04895410	Shah, M	CIPT	02/02/2022	06/14/2022	I	Tre	A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab with or without Dexamethasone and in Combination with Anti-Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma.	Yes		2	0	0		
Celgene Corporation	Multiple	NCT04400591	Shah, M	CIPT	10/10/2020		N/A	Tre	Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release.	Yes		1	4	4		
Celgene Corporation	Multiple Myeloma	NCT04771078	Shah, M	CIPT	06/23/2021		N/A	Tre	Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release.	Yes		4	0	0		
Janssen Research & Development, LLC	Multiple Myeloma	NCT03901963	Shah, M	CIPT	04/30/2020		III	Tre	A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant.	Yes		3	0	1		
Regeneron Pharmaceuticals	Multiple Myeloma	NCT03761108	Shah, M	CIPT	01/08/2019	11/28/2022	I/II	Tre	Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma.	Yes		5	0	13		
Tizona Therapeutics	Multiple	NCT04485013	Stephenson, R	CIPT	01/07/2021		I	Tre	A First-in-Human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors.	Yes		2	5	7		
Immunocore, Ltd	Melanoma, Skin	NCT05549297	Weiss, S	CIPT	03/10/2023		II/III	Tre	Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigators Choice in HLA-A*02:01-Positive Participants with Previously Treated Advanced Melanoma.	Yes		10	0	0		
Karyopharm Therapeutics Inc.	Melanoma, Skin	NCT04768881	Weiss, S	CIPT	05/18/2021	01/31/2023	II	Tre	A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination with Pembrolizumab Recurrent Advanced Melanoma.	Yes		4	0	3		
Lyell Immunopharma, Inc	Melanoma, Skin	NCT05573035	Weiss, S	CIPT	02/13/2023		I	Tre	A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies.	Yes		3	0	0		
Moleculin Biotech, Inc.	Soft Tissue	NCT04887298	Weiss, S	CIPT	11/08/2021		I/II	Tre	Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects with Previously Treated Soft-Tissue Sarcomas with Pulmonary Metastases.	Yes		3	2	2		

Phlogen	Soft Tissue	NCT03420014	Weiss, S	CIPT	07/19/2019	07/26/2022	II	Tre	A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-Targeting Human Antibody-Cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-Line Therapy in Patients with Advanced or Metastatic Soft Tissue Sarcoma.	Yes		4	0	2		
---------	-------------	-------------	----------	------	------------	------------	----	-----	---	-----	--	---	---	---	--	--

### Observational:

National											Total Targeted Accrual		Cancer Center: Primary Accrual Institution		Other Accrual Institution(s)	
Specific Funding Source	Primary Site	Protocol ID	PI	Prog Code	Date Opened	Date Closed	Phase	Primary Purpose	Official Title	Multi-Inst Study?	Entire Study	Your Center	12 Months	To Date	12 Months	To Date
COG	Multiple	NCT00736749	Drachtman, R	CIPT	10/11/2010		N/A	Oth	Umbrella Long-Term Follow-Up Protocol.	Yes		100	4	28		
COG	Multiple	NCT02402244	Drachtman, R	CIPT	02/10/2016		N/A	Oth	Project Every Child: A Registry, Eligibility Screening, Biology and Outcome Study.	Yes		25	50	215	0	27
COG	Leukemia, not otherwise specified	NCT04726241	Drachtman, R	CIPT	07/13/2022		N/A	Scr	Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.	Yes		10	0	0	0	0
NRG	Breast - Female	NCT03188393	Eladoumikdachi, F	CIPT	03/16/2018	12/01/2022	II	Dia	A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery.	Yes		5	0	0		
ECOG	Prostate	NCT03697148	Jang, T	CIPT	11/01/2022		II	Dia	Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer.	Yes		20	0	0		
SWOG	Other Male Genital	NCT04435756	Jang, T	CIPT	09/30/2020		N/A	Hsr	A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors.	Yes		15	7	17		
Externally Peer-Reviewed											Total Targeted Accrual		Cancer Center: Primary Accrual Institution		Other Accrual Institution(s)	
Specific Funding Source	Primary Site	Protocol ID	PI	Prog Code	Date Opened	Date Closed	Phase	Primary Purpose	Official Title	Multi-Inst Study?	Entire Study	Your Center	12 Months	To Date	12 Months	To Date
NMDP	Other Hematopoietic	NCT01166009	Braunschweig, I	CIPT	04/22/2006		N/A	Oth	A Research Database for Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries.	Yes		1000	96	1703		
NIH	Leukemia, not otherwise specified	R01 CA240360	Cole, P	CIPT	06/13/2020		N/A	Hsr	Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia.	Yes	240	50	0	0		
The Radiosurgery Society	Multiple	NCT01885299	D'Ambrosio, D	CIPT	01/08/2019		N/A	Hsr	RSSearch Patient Registry - A Multi-Institution Registry of SRS/SBRT Procedures.	Yes		100	47	441		
Department of Defense	Prostate	13410996	Deek, M	CIPT; GICG	08/09/2022		N/A	Hsr	Understanding the Role of p53 in the Development and Progression of Oligometastatic Castration-Sensitive Prostate Cancer.	Yes	100	25	0	0	0	0
Moffitt	Multiple	14690	Riedlinger, G	CIPT; GICG	02/02/2016		N/A	Oth	Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer.	Yes		1000	352	4503		
Columbia University	Multiple	112004	Sharma, A	CIPT	08/05/2020	07/21/2022	N/A	Hsr	Pediatric Hematology, Oncology, and Stem Cell Transplant Retrospective and Prospective Patient Database for all Patients Tested for COVID-19 Including Demographics, Clinical Courses, and Outcomes.	Yes		5	0	0		
Institutional											Total Targeted Accrual		Cancer Center: Primary Accrual Institution		Other Accrual Institution(s)	
Specific Funding Source	Primary Site	Protocol ID	PI	Prog Code	Date Opened	Date Closed	Phase	Primary Purpose	Official Title	Multi-Inst Study?	Entire Study	Your Center	12 Months	To Date	12 Months	To Date
CINJ	Multiple	112001	Cole, P	CIPT	11/01/2020		N/A	Hsr	Concordance of self-reported Race and Ethnicity with Hospital Records Among Pediatric Patients.	No	250	125	134	237		
CINJ	Breast	042105	Haffty, B	CIPT	10/01/2021		N/A	Hsr	Evaluation of Depression and Anxiety in Breast Cancer Patients Using Validated Questionnaires.	No	300	200	0	0		
CINJ	Multiple	192103	Hinrichs, C	CIPT; CMI	02/16/2022		N/A	Bas	Long Term Follow Up for Subjects Treated with Gene Therapy Cell Products at Rutgers Cancer Institute.	No	200	5	0	0		

CINJ	Multiple	112010	Moerdler, S	CIPT	05/21/2021		N/A	Oth	Pediatric Hematology/Oncology Providers Perspectives on Biosimilar Use.	No		125	0	0		
CINJ	Multiple	132105	Saraiya, B	CIPT; CPC	01/04/2022		N/A	Hsr	Exploring Patient and Caregiver Perspectives and Experiences with Financial Toxicity.	No	70	35	0	0		
CINJ	Multiple	131317	Toppmeyer, D	CIPT	11/18/2014		N/A	Oth	Familial Cancer Registry	No	10000	100	0	1060		
<b>Industry</b>											<b>Total Targeted Accrual</b>		<b>Cancer Center: Primary Accrual Institution</b>		<b>Other Accrual Institution(s)</b>	
Specific Funding Source	Primary Site	Protocol ID	PI	Prog Code	Date Opened	Date Closed	Phase	Primary Purpose	Official Title	Multi-Inst Study?	Entire Study	Your Center	12 Months	To Date	12 Months	To Date
OncoHost	Melanoma, Skin	NCT04056247	Berger, A	CIPT	01/25/2021		N/A	Hsr	Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti-Cancer Treatments.	Yes		6	1	9		
Nateria, Inc.	Colon; Rectum	NCT04264702	Berim, L	CIPT	06/29/2020	03/17/2023	N/A	Dia	Study of ctDNA Guided Therapy in Colorectal Cancer (BESPOKE).	Yes		8	8	55		
ACCRU	Colon	NCT03765736	Boland, P	CIPT	02/25/2021		N/A	Scr	Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy (COLOMATE).	Yes		20	1	3		
MorphoSys AG	Non-Hodgkin's Lymphoma	NCT04981795	Evens, A	CIPT	04/25/2022		IV	Hsr	Prospective Multicenter Observational Study of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Starting Second- or Third-line Therapy and not Receiving Autologous Stem Cell Transplant.	Yes		20	1	1		

### Ancillary or Correlative:

<b>National</b>											<b>Total Targeted Accrual</b>		<b>Cancer Center: Primary Accrual Institution</b>		<b>Other Accrual Institution(s)</b>	
Specific Funding Source	Primary Site	Protocol ID	PI	Prog Code	Date Opened	Date Closed	Phase	Primary Purpose	Official Title	Multi-Inst Study?	Entire Study	Your Center	12 Months	To Date	12 Months	To Date
COG	Kidney	NCT00898365	Drachtman, R	CIPT	06/02/2006		N/A	Bas	Renal Tumors Classification, Biology and Banking Study.	Yes		5	0	22		
COG	Multiple	NCT00904241	Drachtman, R	CIPT	02/07/2001		N/A	Bas	Neuroblastoma Biology Studies.	Yes		100	3	36	0	1
Alliance	Lung	NCT02194738	Jabbour, S	CIPT	12/11/2015	12/03/2020	N/A	Scr	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A Screening Trial for A081105 and E4512.	Yes		2	1	25	0	16
<b>Externally Peer-Reviewed</b>											<b>Total Targeted Accrual</b>		<b>Cancer Center: Primary Accrual Institution</b>		<b>Other Accrual Institution(s)</b>	
Specific Funding Source	Primary Site	Protocol ID	PI	Prog Code	Date Opened	Date Closed	Phase	Primary Purpose	Official Title	Multi-Inst Study?	Entire Study	Your Center	12 Months	To Date	12 Months	To Date
NMDP	Leukemia, not otherwise specified	NCT04920474	Braunschweig, I	CIPT	11/17/2006		N/A	Bas	Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation , Other Cellular Therapies and Marrow Toxic Injuries.	Yes		500	9	860		
NIH	Multiple	001813	Evens, A	CIPT; CMI; GICG	04/09/2018	07/11/2022	N/A	Bas	Determining Treatment Sensitivity in B-Cell Lymphoma by a Novel Microfluidics-Based NK Cell Immunogenicity Platform.	No	30	5	0	5		
NIH	Non-Hodgkin's Lymphoma	001818	Evens, A	CIPT; CMI; GICG	07/19/2018	07/07/2022	N/A	Bas	An Integrated Acoustofluidic Droplet-Sorting Platform for Classification of Lymphocyte Activity and Functional Phenotyping at Single Cell Level.	No	30	5	0	0		
Univ. of Pennsylvania	Lung	NCT04305613	Jabbour, S	CIPT	03/14/2022		N/A	Hsr	Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated with Chemoradiation Therapy: A Prospective Longitudinal Cohort.	Yes		50	15	15		
NCI	Breast	1 R01 CA233662-01A1	Ganesan, S	CIPT; GICG	09/04/2019		N/A	Bas	Evolution and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in Breast Tumor Microenvironment.	No	1200	1000	6	69		
<b>Institutional</b>											<b>Total Targeted Accrual</b>		<b>Cancer Center: Primary Accrual Institution</b>		<b>Other Accrual Institution(s)</b>	
Specific Funding Source	Primary Site	Protocol ID	PI	Prog Code	Date Opened	Date Closed	Phase	Primary Purpose	Official Title	Multi-Inst Study?	Entire Study	Your Center	12 Months	To Date	12 Months	To Date
CINJ	Melanoma, Skin	002122	Berger, A	CIPT	04/08/2021		N/A	Bas	Evaluation of Circulating Tumor DNA (ctDNA) in Patients with Stage IIB and IIC Malignant Melanoma .	No	20	0	6	14		



CINJ	Multiple	002103	Evens, A	CIPT	01/21/2021		N/A	Bas	A Sample Collection Protocol for the Evaluation of the Standard of Care Use of PDI/PDL1 Inhibitors in Patients with Advanced Cancer During Pregnancy.	No	4	1	0	1		
CINJ	Multiple	192001	Hinrichs, C	CIPT; CMI	12/09/2021		N/A	Bas	Collection of Peripheral Blood Mononuclear Cells (PBMCs) for Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy.	No	500	25	7	16		
CINJ	Multiple	192002	Hinrichs, C	CIPT; CMI	06/17/2021		N/A	Bas	Biospecimen Procurement for Cancer Immunotherapy at Rutgers Cancer Institute.	No	500	25	60	99		
CINJ	Multiple	192101	Hinrichs, C	CIPT; CMI	02/16/2022		N/A	Scr	Screening Protocol for Clinical Trial Eligibility.	No	500	100	45	45		
Neogene Therapeutics	Multiple	002115	Hinrichs, C	CIPT; CMI	08/11/2021		N/A	Bas	A Pilot Trial to Explore Targeting of Personalized Neoantigens with Engineered T Cell Receptor Therapy.	No	120	10	59	86		
CINJ	Multiple	002114	Hochster, H	CIPT	03/16/2021		N/A	Bas	Clinical Trial of Effect of Chemotherapy on Efficacy of Vaccination for SARS-CoV-2.	Yes	140	10	0	24		
CINJ	Multiple	031806	Kim, S	CIPT	12/17/2019		N/A	Bas	Detection & Characterization of Circulating Tumor Cells in Adenoid Cystic Carcinoma.	No	30	30	3	10		
CINJ	Soft Tissue	112103	Moerder, S	CIPT; GICG	09/17/2021		N/A	Bas	Novel Immune Checkpoint Expression on Circulating Tumor Cells of Sarcomas.	No	50	50	0	1		
CINJ	Non-Hodgkin's Lymphoma	011811	Strair, R	CIPT	11/21/2018		N/A	Bas	Analysis of Circulating Lymphoid Cells in Patients With (or Treated For) Non-Hodgkins Lymphoma.	No	36	36	0	3		
CINJ	Multiple	012108	Strair, R	CIPT	03/10/2022		N/A	Bas	Machine Learning-based High-throughput and Integrative Immunological Synapse Quality Evaluation As a Composite Biomarker for Predicting CAR Therapy Efficacy in Immuno-Oncology.	No	36	18	8	8		
CINJ	Leukemia, other; Leukemia, not otherwise specified	022104	Strair, R	CIPT	11/16/2021		N/A	Hsr	Leukemia Inhibitory Factor Levels after Allogeneic Transplantation.	No	30	20	9	9		
<b>Industry</b>											<b>Total Targeted Accrual</b>		<b>Cancer Center: Primary Accrual Institution</b>		<b>Other Accrual Institution(s)</b>	
<b>Specific Funding Source</b>	<b>Primary Site</b>	<b>Protocol ID</b>	<b>PI</b>	<b>Prog Code</b>	<b>Date Opened</b>	<b>Date Closed</b>	<b>Phase</b>	<b>Primary Purpose</b>	<b>Official Title</b>	<b>Multi-Inst Study?</b>	<b>Entire Study</b>	<b>Your Center</b>	<b>12 Months To Date</b>	<b>To Date</b>	<b>12 Months To Date</b>	<b>To Date</b>
Janssen Research & Development, LLC	Multiple Myeloma	NCT05201781	Braunschweig, I	CIPT	03/30/2023		IV	Sup	A Long-Term Study for Participants Previously Treated With Ciltacabtagene Autoleucl	Yes		5	0	0		
Imvax, Inc.	Ovary	102202	Einstein, M	CIPT	10/04/2022		N/A	Bas	Evaluation Of Immunological Responses Against Gynecologic Solid Tumors.	Yes		5	1	1		